EFFORT: Phase II Study of the WEE1 Inhibitor Adavosertib ± Olaparib in PARPi-Resistant Ovarian Cancer

June 4-8, 2021; Online at https://conferences.asco.org/am
Adavosertib with or without olaparib demonstrated clinical activity with a manageable toxicity profile in patients with PARPi-resistant ovarian cancer, regardless of BRCA status.
Format: Microsoft PowerPoint (.ppt)
File Size: 400 KB
Released: June 8, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Gilead Sciences, Inc.
GlaxoSmithKline
Merck Sharp & Dohme Corp.

Related Content

Podcast episode with expert insights on important trial data for ovarian and endometrial cancers from the ESGO 2021 annual meeting, from Clinical Care Options (CCO)

person default Nicole Concin, MD, PhD Released: November 23, 2021

Commentary from Clinical Care Options (CCO): Maria Arcila, MD, discusses recommendations for testing for NRG1 fusions in patients with solid tumors

person default Maria E. Arcila, MD Released: November 16, 2021

Downloadable slideset updated with highlights of key gynecologic oncology studies presented at conferences throughout 2021, from Clinical Care Options (CCO)

Jubilee Brown, MD person default Nicole Concin, MD, PhD Bernard Doger de Spéville, MD, PhD Melissa M. Hardesty, MD, MPH person default Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD Ursula Matulonis, MD David Scott Miller, MD, FACOG, FACS Prof Isabelle Ray-Coquard, MD, PhD Released: November 15, 2021

Short slideset on second-generation TRK inhibitors selitrectinib and repotrectinib in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: November 9, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue